Weight loss on a GLP-1 always stops eventually. In STEP 1, the semaglutide curve was almost flat from week 52 to week 68. In SURMOUNT-1, the tirzepatide curve flattened at about the same point. Nobody in either trial had stopped their injections.
The plateau is built into how these drugs work and how bodies respond to losing weight. On a low dose or microdosing protocol it usually arrives sooner and at a smaller total loss, which surprises people who expected slow and steady to mean slow and endless. The question worth asking is rarely "what is wrong?" More often it is "is this where I am meant to land at this dose, and am I happy here?"
This article covers what the trial curves show, why appetite feedback does more to stop weight loss than metabolic slowdown, how to tell a real plateau from a month of scale noise, what the dose finding data say about lower doses, which changes have evidence behind them, and why stopping the medication at a plateau is usually the worst of the available options.
Key Takeaways
- GLP-1 weight loss levels off while treatment continues. In STEP 1 (semaglutide 2.4 mg) mean loss reached about 15 percent and flattened after week 52; in SURMOUNT-1 (tirzepatide 15 mg) it reached about 21 percent and flattened around week 60.
- Each dose settles at its own weight. In the O'Neil 2018 dose finding trial, daily semaglutide at 0.05 mg produced 6.0 percent loss at 52 weeks and 0.4 mg produced 13.8 percent. A lower dose plateaus lower, not later.
- Rising appetite drives the plateau more than a slowing metabolism. Polidori and colleagues estimated in 2016 that intake rises about 100 calories a day per kilogram lost, roughly four times the 20 to 30 calorie fall in energy expenditure.
- Day to day scale readings swing by 0.5 to 1.5 kilograms from water and sodium alone. A 7 day rolling average and a waist measurement are needed to tell a true plateau from noise.
- Stopping at a plateau usually leads to regain. In STEP 4, people switched to placebo regained 6.9 percent of body weight over 48 weeks, while those who continued lost a further 7.9 percent.
Is it normal for weight loss to stop on a GLP-1?
Every trial curve bends and then flattens
A plateau is the expected shape of GLP-1 weight loss, not a sign of failure. In the STEP 1 trial of 1,961 adults, mean weight on semaglutide 2.4 mg fell fastest in the first 20 weeks, slowed through the middle of the trial, and moved by less than half a percentage point between week 52 and week 68. SURMOUNT-1 followed 2,539 adults on tirzepatide, and the 15 mg arm showed the same bend, with the curve flattening at about 21 percent loss around week 60.
Trial averages hide a lot of individual variety. In STEP 1, about a third of participants lost 20 percent or more of their body weight and roughly one in seven lost under 5 percent. Some people plateau at month five and some are still losing at month fourteen. What the curves show is that almost everyone plateaus at some point, and that the plateau arrives with the drug still on board.
The track progress article on this site describes the measurements that give the fullest picture. For the plateau question in particular, the trial curves are useful as a reference point: a person nine months into a full dose protocol who has stopped losing is, statistically, right where most trial participants were.
When Did Weight Loss Flatten in the Pivotal Trials?
Mean percent change in body weight by week in the active arms of STEP 1 (semaglutide 2.4 mg) and SURMOUNT-1 (tirzepatide 15 mg), read from the published trajectory figures
- Semaglutide 2.4 mg (STEP 1)
- Tirzepatide 15 mg (SURMOUNT-1)
Both curves flatten while dosing continues. SURMOUNT-1 ran to week 72; the final point is shown at week 68 for alignment. Values are approximate readings of group means, and individual curves vary widely around them.
Why does weight loss stop if I am still taking the drug?
Appetite climbs back faster than expenditure falls
Weight loss stops when daily calorie intake rises to meet daily calorie expenditure, and on a GLP-1 both sides of that equation move. Expenditure falls because a smaller body costs less to run. Kevin Hall's energy balance model, published in The Lancet in 2011, puts the drop at roughly 20 to 30 calories a day for every kilogram lost. Someone who has lost 12 kilograms therefore needs about 300 fewer calories a day to stay where they are.
Appetite moves further. Polidori and colleagues analysed 153 people in a trial of canagliflozin, a diabetes drug that makes the kidneys excrete glucose calories without affecting appetite directly, and calculated in 2016 that spontaneous food intake rose by about 100 calories a day for each kilogram lost. That appetite response is roughly four times the size of the fall in expenditure. The metabolic adaptation article on this site covers the expenditure side in detail; the appetite side is the bigger lever and gets far less attention.
A GLP-1 dampens the appetite response without abolishing it. In the first weeks, the drug cuts intake by several hundred calories a day and the scale moves quickly. As weight falls, hunger signals from ghrelin and falling leptin, described in the hunger hormones article on this site, rise steadily against the drug's brake. At some weight the two forces balance, intake matches expenditure, and the scale stops. That weight is the plateau.
Which Pushes Back Harder: Metabolism or Appetite?
Estimated change in calories per day after 5, 10, and 15 kg of weight loss. Expenditure from the Hall et al 2011 model (about 25 kcal per kg); appetite from Polidori et al 2016 (about 100 kcal per kg)
- Energy expenditure
- Appetite drive (spontaneous intake)
The appetite estimate comes from people not taking a GLP-1, so it describes the push the drug has to hold back rather than what a GLP-1 user actually eats. Both figures are population averages with wide individual spread.
What Does a Plateau Look Like in Calories?
Modelled daily energy intake and expenditure over 13 months for a 100 kg adult starting a GLP-1. The gap between the lines is the daily deficit; where they meet, weight stops changing
- Energy expenditure
- Energy intake
Intake does not stay at its early low. It drifts upward month by month as appetite feedback builds, while expenditure drifts down with body size. This is an illustrative model built on the Hall and Polidori estimates, not measured data from a GLP-1 trial.
How do I tell a real plateau from scale noise?
Four to six weeks of rolling averages, plus a tape measure
A real plateau shows up as a flat 7 day rolling average for four to six weeks, alongside a waist measurement that has also stopped moving. Single weigh ins cannot answer the question. Body water alone shifts morning weight by 0.5 to 1.5 kilograms from one day to the next, driven by the previous day's sodium and carbohydrate intake, bowel contents, sleep, and hard training. On a low dose protocol losing 0.25 kilograms a week, a month of real loss is about 1 kilogram, which is smaller than a single salty restaurant meal can add overnight.
Women have an extra source of noise. Water retention in the luteal phase of the menstrual cycle commonly adds 0.5 to 1 kilogram in the week before a period, and comparing a luteal phase weigh in with a follicular one can erase two or three weeks of progress on paper. The women over 40 article on this site notes that perimenopause makes this pattern less predictable. Comparing the same cycle day month to month is a cleaner test.
There is no official definition of a GLP-1 plateau. A common working rule among obesity clinicians is less than 1 percent of body weight lost over four to six weeks, judged on the rolling average. Anything shorter is usually a stall. Stalls of two or three weeks are routine in every weight loss trial dataset and end on their own.
Can a Month of Real Loss Look Like a Plateau on the Scale?
Illustrative 28 days of morning weigh ins (kg) for someone losing 0.25 kg a week, with normal water swings, against the 7 day rolling average
- Daily weigh in
- 7 day rolling average
Day 10 reads higher than day 1, and days 25 and 26 read higher than day 20, yet the average falls by a kilogram across the month. These are simulated readings to show the pattern, not data from an individual.
Do lower doses plateau sooner?
Each dose has its own landing point
Lower doses plateau at a smaller total loss, and the best evidence comes from the only trial that tested semaglutide across a wide range of low doses. O'Neil and colleagues randomised 957 adults in 2018 to daily semaglutide at 0.05, 0.1, 0.2, 0.3, or 0.4 mg, or to placebo or liraglutide, for 52 weeks. Mean weight loss ran from 6.0 percent at 0.05 mg to 13.8 percent at 0.4 mg, against 2.3 percent on placebo. The weekly equivalent of the lowest dose is roughly 0.35 mg, well inside the range microdosing protocols use.
The trial's weight curves showed each dose flattening at its own level rather than the low doses catching up given more time. That pattern matters for anyone on a microdose. A protocol built for fewer side effects, gentler appetite suppression, and slower loss will usually settle at a smaller total loss than the full dose headline figures of 15 to 21 percent. The gentle ramp article on this site explains why many people choose that trade deliberately.
The same data explain why raising the dose usually restarts loss. More drug holds back more of the appetite response, so the balance point moves to a lower weight. Whether that is the right move depends on the side effect burden, the person's health goals, and whether the current weight is already a healthy and sustainable one. That judgment belongs with the prescriber.
Where Did Each Semaglutide Dose Settle After a Year?
Mean percent change in body weight at week 52 by daily semaglutide dose, O'Neil et al 2018 phase 2 dose finding trial (n = 957)
The two lowest doses, highlighted, sit in the range many microdosing protocols use when converted to a weekly amount. Participants were adults with obesity and without diabetes. Daily dosing was used in this trial; approved products are weekly, and the conversion is approximate.
What actually helps when weight loss stalls on a GLP-1?
Six checks to bring to the prescriber
The options below are context for a conversation with the prescriber, not a plan to follow alone. Most of them target the appetite side of the balance, because that side is larger.
A rolling 7 day average, a weekly waist measurement at the navel, and the same cycle day comparison for women. Many apparent plateaus disappear once noise is removed, and the track progress article on this site sets out a simple method.
Intake creep usually comes from snacks and liquid calories rather than meals, while protein tends to fall. A target of roughly 1.2 to 1.6 grams per kilogram of goal body weight keeps satiety up and protects lean mass, as the protein requirements article on this site explains.
Resistance training rarely moves the scale much, but it shifts the composition of any further loss toward fat and can keep the waist shrinking while weight holds. It also protects the muscle that sets part of resting expenditure.
One night of short sleep raises next day hunger and intake in controlled studies, and alcohol adds calories while lowering restraint. The sleep and alcohol articles on this site cover both. These are the two habits most often found to have drifted by month six.
If the plateau has lasted more than six weeks and the weight is still above the agreed goal, the prescriber may consider a dose adjustment. The O'Neil data suggest this usually restarts loss, at the cost of more side effects.
A plateau at a weight with better blood pressure, glucose, and lipid numbers, a smaller waist, and tolerable side effects is often a good outcome. Holding that weight long term is the harder and more valuable job.
What happens if I stop the GLP-1 because I have plateaued?
The drug is still working, just on holding rather than losing
Stopping a GLP-1 at a plateau usually leads to substantial regain, because the drug is what was holding back the appetite response. STEP 4 tested this directly. All 803 participants took semaglutide 2.4 mg for 20 weeks and lost a mean 10.6 percent of body weight. They were then randomised: those who continued lost a further 7.9 percent by week 68, while those switched to placebo regained 6.9 percent.
The STEP 1 extension followed participants for a year after the trial ended and found they had regained about two thirds of the weight they lost. Improvements in blood pressure, HbA1c, and lipids moved back toward baseline with the weight. SURMOUNT-4 found the same pattern with tirzepatide.
Seen this way, a plateau is often the phase where the medication is doing its most important work. The maintenance article on this site covers the approaches being studied for holding weight at lower doses, including the rationale for tapering rather than stopping outright. Any change should be planned with the prescriber.
What Happened When People Stopped After 20 Weeks?
Percent change in body weight from week 20 to week 68 in STEP 4 (n = 803), after all participants had lost a mean 10.6 percent on semaglutide 2.4 mg
STEP 4 used the full 2.4 mg dose and abrupt switching to placebo. No trial has yet tested what happens when a microdose is stopped or tapered, and the regain pattern at lower doses is unknown.
What is still unknown about plateaus on low doses?
Two gaps worth naming
No trial has followed people on a deliberate microdosing protocol long enough to describe where and when they plateau. The O'Neil 2018 trial is the closest evidence, and it used daily injections over 52 weeks in people with obesity, not the weekly low doses and flexible schedules that microdosing protocols often use. The assumption that a microdose settles in proportion to its dose is reasonable, but it has not been measured.
The Polidori appetite estimate also has limits. It came from people taking canagliflozin, a drug that causes calorie loss through the urine, and describes the appetite push in people with no GLP-1 on board. How much of that push a low dose GLP-1 holds back, and whether the brake weakens over years, is not known. Tolerance to the appetite effect of GLP-1 drugs has been proposed but not clearly demonstrated in the long term trials.
Frequently Asked Questions
Selected References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021. Weight trajectory over 68 weeks and categorical weight loss outcomes.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022. Weight trajectory over 72 weeks by dose.
- O'Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. The Lancet, 2018. Weight loss at 52 weeks by daily semaglutide dose.
- Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity (STEP 4). JAMA, 2021. Continuation versus withdrawal after 20 weeks.
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022. Regain of about two thirds of lost weight within a year.
- Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA, 2024. Regain after tirzepatide withdrawal.
- Hall KD, Sacks G, Chandramohan D, et al. Quantification of the effect of energy imbalance on bodyweight. The Lancet, 2011. Energy expenditure change per kilogram lost and the dynamic energy balance model.
- Polidori D, Sanghvi A, Seeley RJ, Hall KD. How strongly does appetite counter weight loss? Quantification of the feedback control of human energy intake. Obesity, 2016. The roughly 100 kcal per day per kilogram appetite estimate.
- Hall KD, Kahan S. Maintenance of lost weight and long-term management of obesity. Medical Clinics of North America, 2018. Why plateaus arrive and the role of appetite feedback.
This article is for general educational purposes only and does not constitute medical advice, diagnosis, treatment, or a recommendation to start, stop, switch, or change the dose of any medication. Semaglutide, tirzepatide, and all other GLP-1 receptor agonists are prescription medicines, and the choice of product, dose, and any low dose or microdosing approach should be decided and monitored by a qualified healthcare provider. The energy balance, appetite, and scale reading charts are illustrative models built from published population estimates, not measurements of any individual, and trial curves are approximate readings of published group means. Do not change or stop a GLP-1 dose because of a plateau without speaking to the prescriber. Nothing here is intended to diagnose, prevent, treat, or cure obesity or any other condition, and no low dose or microdosing approach described in this article has been shown in trials to be safe or effective outside the specific trial conditions cited. Individual results vary.
Smaller Doses. Sharper Protocols.
Metabolic health you can measure, built around a dose designed to work with your body rather than against it.
Find Your Protocol